Considerations for use of direct oral anticoagulants in arterial disease

Deborah M Siegal1,2, Sonia S Anand3,4,5

  • 1Department of Medicine University of Ottawa Ottawa ON Canada.

Insights

Direct oral anticoagulants (DOACs) show promise in managing cardiovascular diseases like stroke and peripheral arterial disease. This review examines DOACs alongside antiplatelet therapies for better patient outcomes.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Cardiovascular diseases caused 18 million deaths in 2017.
  • Despite advances, patients face significant risks of recurrent cardiovascular events.
  • Effective anticoagulation strategies are crucial for managing these conditions.

Purpose of the Study:

  • To review randomized clinical trials on direct oral anticoagulants (DOACs).
  • To evaluate DOACs in acute coronary syndromes, ischemic stroke, and peripheral arterial disease.
  • To present considerations for combined DOAC and antiplatelet therapy.

Main Methods:

  • Narrative review of randomized clinical trials.
  • Focus on studies evaluating DOACs for specific cardiovascular conditions.
  • Analysis of treatment strategies including single/dual antiplatelet therapy and low-dose DOACs.

Main Results:

  • DOACs are evaluated for acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease.
  • The review discusses the use of single antiplatelet therapy, dual antiplatelet therapy, or low-dose DOACs with antiplatelet therapy.
  • Considerations for optimizing treatment regimens are presented.

Conclusions:

  • DOACs represent an important therapeutic option in managing various cardiovascular conditions.
  • Combining DOACs with antiplatelet therapy requires careful consideration of risks and benefits.
  • Further research may refine optimal anticoagulation strategies for these patient populations.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
86
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
792
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
89
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
63